Affordable Access

Publisher Website

The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer

Authors
Journal
Journal of Infection and Public Health
1876-0341
Publisher
Elsevier
Volume
5
Identifiers
DOI: 10.1016/j.jiph.2012.09.004
Keywords
  • Egfr
  • Lung Cancer
  • Inhibitors
Disciplines
  • Medicine

Abstract

Summary Targeting epidermal growth factor receptor (EGFR) is an important treatment option for non-small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in NSCLC in first line and subsequent lines, including maintenance in empiric fashion or in patients with tumors harboring the EGFR mutations. In this manuscript, we will review in details the evolutions of these targeted therapy in the management of NSCLC.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Epidermal growth factor receptor (EGFR) exon 20 mu...

on Investigational New Drugs December 2014

Epidermal growth factor receptor (EGFR) inhibitors...

on Progress in drug research. For... 2005

Epidermal growth factor receptor (EGFR) signaling...

on Journal of Clinical Oncology Sep 20, 2012

Mutations in the epidermal growth factor receptor...

on General thoracic and cardiovas... March 2008
More articles like this..